Bioderma Sebium Kerato+ Body is an anti-blemish soothing spray specifically developed to meet the needs of body acne. A dermatological solution guarantying high efficacy combined with high tolerance to visibly reduces reds spots, marks and redness from 7 days and helps prevent their reapparance.
HOW IT WORKS?
Body imperfections such as spots, redness and marks, particularly on the back, shoulders, neck and arms, are a common concern with varying degrees of severity. Developed by Bioderma’s advanced research, this dermatological innovation is the 1st body spray to effectively and quickly act on imperfections without irritating the skin. This unique ecobiological formula has been developed with a highly effective combination of dermatological actives : Lilac extract, which reduces imperfections, marks and redness by limiting the accumulation of dead cells, regulating sebum production, decreasing inflammation and slowing the mechanisms of hyperpigmentation, works together with niacinamide, known for its soothing and anti-inflammatory properties on acne lesions. Salicylic acid further complements the action by smoothing and purifying the skin. The Fluidactiv™ technology, by biologically normalizing the quality of sebum, helps prevent pore clogging and thus the appearance of new blemishes.
RESULTS:
Formulated with Lilac extract, Fluidactiv™ technology, Niacinamide and Salicylic acid, Bioderma Sebium Kerato+ Body acts on surface and in depth to eliminate blemishes, pimples, blackheads and marks on the body while preserving skin tolerance.
ANTI-SPOTS, MARKS, REDNESS AND HELPS PREVENT THEIR REAPPARANCE
-70% pimples and action on redness and marks (2a)
REDUCES IMMEDIATLY & ALL DAY LONG SENSATIONS OF DISCOMFORT
100% felt immediate soothing (1)
91% imperfections are less uncomfortable (2b)
CLEAR SKIN FOR A CONFIDENT LIFE
97% Skin is smoother (2b)
2X Less apprehension of exposing their backs in public (3)
Made in France
Formulated in our own research laboratory in Aix-en-Provence
Prescribed by dermatologists
Tested under dermatological supervision
Very good tolerance. Clinically proven efficacy.
(1) Clinical study on 34 subjects with light to moderate acne-prone skin for 56 days, Brazil 2024. Evaluation using a) clinical grading, b) self-asessement and c) CADI questionnaire for 56 days
(2) Clinical study on 21 subjects with acne-prone skin for 21 days, France, 2024. Self-assessement
Other options
